Oncology / Cancer
12 Results were found on Technologies
Sub Category Name
Therapeutic Targeting of CD45: A Novel Approach to Overcome Immunotherapy Resistance
Revolutionizing Cancer Immunotherapy While immune checkpoint inhibitors have transformed cancer treatment, only 50% of patients fail to respond, with resistance being a major challenge, particularly in aggressive cancers such as triple-negative breast cancer (TNBC). TNBC accounts for 15–20% of breast cancer cases and is often diagnosed at advanced stages, with current therapies offering limited efficacy. […] Read More >
Pharmacological Activation of the cAMP Signaling Pathway Enhances the Function of Cord Blood – Hematopoietic Stem Cells
Allogeneic Hematopoietic Stem Cell Transplantation is a curative therapy for many blood disorders, including leukemias and inherited blood diseases. It involves depleting a patient’s diseased bone marrow by cytotoxic therapies and then regenerating a healthy hematopoietic system by transplantation of healthy Hematopoietic Stem Cells (HSCs). UNMET NEED Cord blood is an attractive source for stem […] Read More >
Restoring Immunity Against GI Cancers
BACKGROUND GI cancers cause over 3.5 million deaths per year globally, accounting for 35% of all cancer-related deaths. Colorectal carcinoma (CRC) is the world’s second leading cause of cancer death. Current immunotherapy treatments for CRC are hamstrung by low response rate, acquired resistance, relapse and severe side effects. ImmuNovation presents a disruptive nanomodular technology utilizing […] Read More >
Novel Anti-Tumor Response treatment targeting ErbB receptors and Nucleolin interactions
ErbBs subfamily receptors are mediators of cell growth signals. They have long been associated with a wide variety of lung, ovarian, colon, breast, prostate, and other carcinomas. Nucleolin is a major nucleolar protein of growing eukaryotic cells and is present on the cell surface of a range of cancers. Recently, a robust oncogenic interaction between […] Read More >
Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer
Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >
Therapeutic Vaccine for the Treatment of Cancer
An active cancer vaccine strategy targeting tumor-associated carbohydrate antigens expressed on tumor cells using biomimetic glyconanoparticles generated from unique red blood cells. The resulting sustained immune response inhibits tumor growth. THE NEED While envisioned already in 1891, only a few cancer vaccines have been approved by the FDA thus far. The key barriers to their […] Read More >
A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues
UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >
An Oncolytic Virus That Exploits Immune Defects of Cancer Cells
An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy. Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEED On Nov. 2015 the FDA approved the first oncolytic virus based treatment. […] Read More >
Targeting Bone Neoplasms and Other Cancers with Novel Combined Anticancer and Anti-Angiogenic Polymer Therapeutics
Anti-cancer NanoTherapyUtilizing unique nano-technology to develop targeted combination nanomedicines that were shown to be synergistic, effective and safe for treating cancer TechnologyWe have developed a new platform technology for the treatment of cancer and bone metastases using combined targeted nano-sized polymers that deliver chemotherapeutics creating a new class of effective and safer molecules. The novel […] Read More >
Therapeutic Targeting of PD-1/PD-L1 blockade by Novel Small-molecule Inhibitors
Interactions between programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) lead to the evasion of cancer cells from an efficient immune response. The inhibition of PD-L1/PD-1 has prevented or reversed exhausted T cells, thus enhancing antitumor T-cell responses. In fact, immune checkpoint blockade targeting the PD-1 axis has become one […] Read More >
Leveraging Gene Panel Sequencing Data for Mutational Signature Analysis with Applications to Personalized Treatment
UNMET NEED Mutational signatures and their exposures are key to understanding the processes that shape cancer genomes with applications to diagnosis and treatment. Yet current signature analysis approaches are limited to relatively rich mutation data that comes from whole-genome or whole-exome sequencing. Recently, orders of magnitude sparser data sets from gene panel sequencing have become […] Read More >
Homocysteine fibrillar assemblies display crosstalk with Alzheimer’s disease amyloid polypeptide
High levels of homocysteine (Hcy) are reported as a risk factor for Alzheimer’s disease (AD). Correspondingly, inborn hyperhomocysteinemia is associated with an increased predisposition to the development of dementia in later stages of life. Furthermore, despite the apparent association between protein aggregation and AD, attempts to develop a therapy that targets explicitly this process have […] Read More >
